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Prostate cancer and chronic lymphocytic leukemia (CLL) are relatively common malignancies associated with
advanced age. Although immunotherapy-based strategies are used to treat both, currently, there is no overlap
in specific therapies. Sipuleucel-T is an active cellular immunotherapy that improves overall survival for patients
with metastatic castration resistant prostate cancer (mCRPC) but is not typically associated with a decline in
prostate-specific antigen (PSA) following administration. We report the case of a 78-year-old man with mCRPC
and Rai stage 0 CLL who sustained a 12-month decline in both PSA and white blood cell (WBC) count following
treatment with APC8015-2 (an investigational form of sipuleucel-T), as part of the phase II ProACT clinical trial. Two
years later, the patient received commercial sipuleucel-T and again was noted to have a decline in PSA. Exploratory
analysis did not clearly identify any peripheral immune markers associated with response. This case report suggests
that treatment with sipuleucel-T can rarely lead to PSA decline, may have dual activity against both prostate cancer
and CLL, and that these findings warrant further investigation.
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Prostate cancer is the most common non-skin malig-
nancy affecting men and is responsible for the majority
of cancer deaths in men in the United States. The first-
line treatment of metastatic prostate cancer includes
androgen deprivation therapy (ADT), which leads to a
varying period of disease control. Eventually, the disease
progresses despite ADT, representing the castration re-
sistant disease state. Treatment options for metastatic
castration resistant prostate cancer (mCRPC) in the past
decade have expanded greatly, with five new agents
recently approved by the Food and Drug Administration
(FDA), including the first-in-class autologous cellular
immunotherapy, sipuleucel-T (Provenge®) [1, 2].* Correspondence: evanyu@uw.edu
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unless otherwise stated.Sipuleucel-T is produced by ex vivo activation of
patient-derived peripheral blood mononuclear cells by
incubation with a fusion protein, PA2024, comprised
of granulocyte-macrophage colony-stimulating factor
(GM-CSF) and prostatic acid phosphatase, which is
expressed on over 95% of prostate cancers [3]. The result-
ing autologous product containing activated antigen-
presenting cells, sipuleucel-T, is subsequently infused into
the patient. The randomized phase III IMPACT clinical
trial demonstrated a 4.1-month improvement in median
overall survival in asymptomatic or minimally symptomatic
men with mCRPC treated with sipuleucel-T compared to
those treated with control and led to the FDA approval of
sipuleucel-T in April 2010, representing the first approved
immunotherapy for prostate cancer [1].
Chronic lymphocytic leukemia (CLL) is the most
common leukemia diagnosed in the United States and
Western world. CLL is a B cell chronic lymphoprolifera-
tive neoplasm that occupies one end of a single diseaseThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lymphoma (SLL), a mature, peripheral B cell neoplasm,
at the other end. Like prostate cancer, CLL is a disease
associated with older age as well as with a highly variable
clinical course ranging from indolent disease requiring
no treatment to aggressive, lethal disease [4, 5]. The
modified Rai and Binet systems of classification have
been clinically useful in prognosis and therapeutic man-
agement. Therapy varies based on clinical, prognostic,
and molecular features, and options include nucleoside
analogs, monoclonal antibodies, chemotherapy, selective
kinase inhibitors, and autologous and allogeneic im-
munotherapy [6]. More recently, promising antitumor
effects have been observed using T cells containing
chimeric antigen receptors (CAR) in patients with ad-
vanced CLL [7–9], providing compelling evidence that
immune-based therapies may be effective in CLL.
We report the case of a patient with mCRPC who also
had Rai stage 0 CLL. He was initially treated with
APC8015-2 (an investigational form of sipuleucel-T)
as part of a clinical trial and later with commercial
sipuleucel-T.
Case presentation
Initial diagnosis and treatment
The patient was initially diagnosed with localized
Gleason 7 prostate cancer in 1989, underwent radical
prostatectomy in 1990, and received salvage radiation
in 1994, followed by an undetectable prostate-specific
antigen (PSA).
In December of 2005, the patient had an episode of
gross hematuria and underwent transurethral resection
of bladder tumor for presumed bladder cancer. He sub-
sequently underwent cystectomy on March 8, 2006 with
pathology unexpectedly showing metastatic prostate
adenocarcinoma, Gleason 4+5. Post-cystectomy, PSA
was 28.48 ng/mL on March 28, 2006, and he was started
on ADT on May 2, 2006. He reached PSA nadir of
0.19 ng/mL in November 2006, which was followed
by a slowly rising PSA, representing castration-resistant
disease.
In November of 2008, 2 years after initiation of ADT,
PSA rose to 7.35 ng/mL. He was then started on ketoco-
nazole 400 mg PO daily, which was discontinued in
April 2009 (PSA 3.93 ng/mL) due to diarrhea attributed to
the ketoconazole. PSA declined to a nadir of 0.04 ng/mL in
August 2009 and later began to rise again.
Treatment on phase II ProACT trial
In June of 2010, the patient’s PSA increased to 9.08 ng/mL.
Restaging with CT and bone scans revealed a new bone
lesion in the right sixth rib. He was enrolled in the phase II
treatment of PROstate Cancer with Active Cellular Im-
munoTherapy (ProACT) dosing study of sipuleucel-T(also referred to as APC8015) in men with mCRPC. In
this study, eligible patients were randomized to receive
either sipuleucel-T, manufactured using the FDA-
approved standard 10 μg/mL concentration of PA2024,
or a product manufactured in a similar manner to
sipuleucel-T but using a lower concentration of PA2024:
5 μg/mL (APC8015-5) or 2 μg/mL (APC8015-2).
Of note, the patient had been diagnosed with Rai stage
0 chronic lymphocytic leukemia with a baseline white
blood cell (WBC) count of 17.21 × 109 cells/L and PSA
of 23.68 ng/mL at time of starting study (Fig. 1).
The patient received three study infusions of study
drug with the final dose administered on December 2,
2010. Subsequent unblinding revealed that he had been
randomized to receive APC8015-2, the investigational
form of sipuleucel-T produced using 2 μg/mL of
PA2024. Correlative markers drawn for the ProACT
study demonstrated that CD54 upregulation (a measure
of product potency and antigen-presenting cell activa-
tion [1]) was low and overall immune responses were
low to undetectable, as was cytokine production during
the product manufacture (data not shown).
Approximately 6 months after study treatment, PSA
had declined from 23.68 to a nadir of 0.25 ng/mL on
May 4, 2011. In addition, WBC declined from 17.21 to
9.45 × 109 cells/L with an absolute lymphocyte count
(ALC) of 5.01 × 109 cells/L, despite the fact that the pa-
tient was not receiving concurrent treatment for CLL;
ALC was not consistently measured and is reported
when available. This suggested that the APC8015-2 he
received as part of the ProACT study rendered control
of not only his prostate cancer but potentially also his CLL.
Treatment with commercial sipuleucel-T
By April 16, 2012, the patient’s PSA, WBC, and ALC
rose to 6.53, 9.75, and 5.55 ng/mL, respectively. He was
subsequently retreated with commercial sipuleucel-T
(produced using 10 μg/mL PA2024) with the final dose
administered on December 31, 2012 (Fig. 1).
With Institutional Review Board (IRB) approval, the
patient consented to undergo exploratory immune mon-
itoring as part of his subsequent retreatment with
commercial sipuleucel-T. Antigen-specific antibody re-
sponses (IgG and IgM) have previously been shown to
correlate with survival after treatment [10]. Analysis of
this patient’s samples showed a pronounced increase in
antibody titers following commercial dose, though sam-
ples beyond week 6 were not collected (Fig. 2). T cell im-
mune function against the prostate cancer antigens, PAP
and PA2024, was measured using T cell proliferation
and IFN-gamma (ELIspot) assays, product manufactur-
ing culture media and serum cytokine profiling (eotaxin,
IP-10, MCP-1, MCP-4, MIP-1β, TARC, IL-17, IL-1B,
IL-6, TNF-α, IFN-γ, IL-10, IL-12 [p70], IL-13, IL-2,
Fig. 1 Pattern of PSA and WBC values following sipuleucel-T treatment. Solid arrows: initial APC8015-2 (investigational form of sipuleucel-T produced
using 2 μg/mL of PA2024) in December 2010 and subsequent treatment with commercial sipuleucel-T (using 10 μg/mL of PA2024) in December 2012.
Open arrows: other therapies. Solid line: PSA prostate-specific antigen; Dotted line: WBC white blood cell count
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to cross-react with CLL antigens (e.g., CD19, CD20, CD23,
CD38, bcl-2, cyclin D1, Zap-70) and CD54 levels (standard
for product release parameters) did not reveal any clear
patterns correlating with the observed PSA and WBC re-
sponses (data not shown).Fig. 2 Pattern of IgG and IgM antibody titers following APC8015 treatment
2 μg/mL of PA2024) in December 2010 and with commercial sipuleucel-T
sipuleucel-T led to more robust IgG and IgM antibody titers. PAP prostatic a
phosphatase and granulocyte-macrophage colony-stimulating factorSubsequent disease course and treatment
Four months after commercial sipuleucel-T treatment,
PSA had increased to 17.38 ng/mL and WBC was stable
at 8.93 × 109 cells/L on April 29, 2013. Unfortunately,
the patient became more symptomatic from bone metas-
tases and received palliative radiation to pubic rami and. Initial APC8015-2 (investigational form of sipuleucel-T produced using
(10 μg/mL PA2024) in December 2012. Rechallenge with commercial
cid phosphatase, PA2024 fusion protein comprised of prostatic acid
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17, 2013 PSA and WBC declined to 13.89 ng/mL and
6.2 × 109 cells/L, respectively, likely reflecting radiation
effect. Most recently, the patient has been treated with
enzalutamide.
Discussion
We report the case of an older patient with mCRPC and
Rai stage 0 CLL who was treated with APC8015-2 (an
investigational form of sipuleucel-T) and observed to
have a dramatic and sustained PSA decline as well as
improvement in his WBC. On subsequent treatment
with commercial sipuleucel-T, he was also noted to have
a PSA decline.
This patient’s initial PSA response to treatment was
noteworthy since a PSA decline of 50 % from baseline
was observed in only approximately 3 % of the partici-
pants in the phase III IMPACT trial [1], though PSA de-
cline was observed at higher rates in the smaller phase I
and II trials [11–13]. Moreover, following subsequent
retreatment with commercial sipuleucel-T, his PSA
declined again, albeit to a lesser degree and for a shorter
duration (and palliative radiation 6 months post-
treatment rendered subsequent PSA values problematic
to interpret). Nevertheless, this pattern of PSA decline
after treatment provides evidence that this patient was
an exceptional responder to sipuleucel-T, although our
exploratory analyses did not uncover a clear association
with cytokine or immune markers.
A second feature in this patient’s case was his concur-
rent diagnosis of CLL and noted decline of WBC and
ALC with study treatment, suggesting the possibility of
cross-reacting antigens and dual therapeutic effect of
sipuleucel-T against both mCRPC and CLL. During re-
challenge with commercial sipuleucel-T, his WBC was in
the normal range at the start of treatment, making it dif-
ficult to interpret the effect of rechallenge on CLL. Pos-
sible explanations include that either the WBC response
following initial treatment was unrelated to sipuleucel-T
or that the CLL response to the initial treatment of
sipuleucel-T was more durable than the PSA response.
A recent report suggests that sipuleucel-T may induce
humoral antigen spread [14]. It is possible that humoral
antigen spread developed to include CLL antigens,
though our exploratory immune monitoring, limited to a
few known CLL antigens, did not support this. An alter-
native explanation is that CLL cells were likely pheresed
along with normal leukocytes and CLL antigens were
inadvertently introduced into the product processing in
sufficient quantities to elicit response not only to
PA2024 but also to CLL antigens.
Of note, active cellular immunotherapy is an approach
being investigated in CLL [15], including one report in
the literature of a dendritic cell vaccine in a small studyof 15 patients using dendritic cells that endocytosed
apoptotic bodies of CLL cells in combination with GM-
CSF elicited anti-CLL immune responses though no
clinical responses [16]. Another study of 22 patients with
advanced CLL demonstrated that a vaccine consisting of
irradiated autologous CLL cells admixed with GM-CSF-
secreting cells administered after allogeneic hematopoe-
tic transplantation resulted in CD8+ T cells consistently
reacting against autologous tumor [17]. In addition, a
prior study using the sipuleucel-T platform but targeted
to multiple myeloma reported promising preliminary
results [18]. Together with our case, these suggest that
the active cellular immunotherapy approach used for
sipuleucel-T may be efficacious when applied to other
cancers with distinct antigens. We speculate that our pa-
tient may have had introduction of not only the PA2024
fusion protein but also the CLL cells during product
manufacture and that his underlying immune system
was intrinsically primed to respond to active cellular
immunotherapy directed at both the intended target
of prostate cancer cells and the bystander target of
CLL cells.
In summary, this interesting case illustrates that the
active cellular immunotherapy sipuleucel-T can result in
dramatic and sustained PSA responses. In addition,
treatment with sipuleucel-T can potentially lead to dual
responses to other malignancies including CLL. We be-
lieve both of these remarkable findings warrant further
investigation.
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